---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-006936"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T20:47:10.068203+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioCryst Q3 ORLADEYO revenue $66M; on track to double 2022 sales; BCX9250 discontinued

## Summary
- Q3 total revenue $75.8M (+85% YoY); net loss $42.5M ($0.23/share) vs $58.8M ($0.33) in Q3 2021.
- ORLADEYO Q3 net revenue $66.0M; full-year 2022 guidance raised to $255M, more than double 2021.
- BCX9930 partial clinical hold lifted; screening resumed; data from ~15 patients expected mid-2023.
- New oral Factor D inhibitor BCX10013 entered clinic; preliminary data expected Q1 2023.
- Discontinued BCX9250 (FOP) program to redirect ~$100M to complement pipeline.

## SEC filing metadata
- accession: 0001171843-22-006936
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184322006936/0001171843-22-006936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184322006936/f8k_110122.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-006936
- JSON: https://secwatch.observer/filing/0001171843-22-006936.json
- Plain text: https://secwatch.observer/filing/0001171843-22-006936.txt

## Key facts
- Earnings Releases
  BIOCRYST PHARMACEUTICALS INC reported third quarter ended September 30, 2022 results: revenue $75.8 million, net income $42.5 million, EPS $0.23 per share.
  - Period: third quarter ended September 30, 2022
  - Revenue: $75.8 million
  - Net income: $42.5 million
  - EPS: $0.23 per share
  - Result: reported results
  source text: For the three months ended September 30, 2022, total revenues were $75.8 million, compared to $41.0 million in the third quarter of 2021 (+85 percent year-over-year (y-o-y)). The increase was primarily due to $66.0 million in ORLADEYO net revenue in the third quarter of 2022. Research and development expenses for the third quarter of 2022 increased to $52.7 million from $50.0 million in the third quarter of 2021 (+6 percent y-o-y), primarily due to additional investment in the HAE program and expenses for BCX9250 prior to its discontinuation, partially offset by reduced costs related to the BCX9930 studies. Selling, general and administrative expenses for the third quarter of 2022 increased to $36.9 million, compared to $35.0 million in the third quarter of 2021 (+6 percent y-o-y). The increase was primarily due to increased investment to support the commercial launch of ORLADEYO. Interest expense was $24.8 million in the third quarter of 2022, compared to $14.1 million in the third qu
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184322006936/0001171843-22-006936-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.